Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)
Closed Posted
- Opportunity number
- RFA-CA-25-007
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Up to $150,000
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Categories
-
- Education
- Health
- Eligible applicants
-
- Non-501(c)(3) Nonprofits
- Small Businesses
- Higher Education Inst. (Public)
- Special District Governments
- Independent School Districts
- Higher Education Inst. (Private)
- 501(c)(3) Nonprofits
- Tribal Governments (Federally Recognized)
- County Governments
- State Governments
- For Profit Organizations
- City/Township Governments
- Tribal Organizations (Not Federally Recognized)
- Public or Indian Housing Auth.
- Other
- Points of contact
-
- NIH OER Webmaster grantsinfo@nih.gov
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Cancer Institute (NCI), part of the Department of Health and Human Services National Institutes of Health, is seeking revision applications from currently funded NCI P50 specialized centers under the Innovative Molecular Analysis Technologies (IMAT) program. The grant opportunity aims to encourage applicants to expand upon original research questions or accelerate parent study progress by incorporating new technical approaches or devices developed through NCI support. Eligible applicants include nonprofits, small businesses, higher education institutions, government entities, and tribal organizations. The primary evaluation criteria will focus on the potential for independent validation and accelerated adoption of emerging cancer research technologies. Applicants must submit their revision applications by December 9, 2025, with the funding opportunity officially posted on December 31, 2024. The NOFO emphasizes promoting interdisciplinary collaboration in developing innovative tools and methods that enable cancer research and scientific discovery.
While specific award amounts are not explicitly stated, the grant will be provided under the Cancer Detection and Diagnosis Research program (CFDA 93.394), which typically supports projects ranging from $200,000 to nearly $3 million. The project periods are generally 2-5 years, with initial awards providing funds for the first budget period. Research will be conducted at the recipient organizations' facilities across the United States, with a focus on translational research that can potentially improve cancer detection, diagnosis, and patient outcomes. The funding is designed to support projects that develop novel technologies, diagnostic tools, and computational methods to advance early cancer identification and risk assessment.
Synopsis
2 versions
Update #2 · Latest ·
The purpose of this Notice of Funding Opportunity (NOFO) is to encourage revision applications from currently funded NCI P50 specialized centers. The applicants should propose to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or device developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this NOFO are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities.As a component of the NCI IMAT program, this NOFO aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.
Update #1 ·
The purpose of this Notice of Funding Opportunity (NOFO) is to encourage revision applications from currently funded NCI P50 specialized centers. The applicants should propose to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or device developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this NOFO are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this NOFO aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.
Files
| File | Type | Posted |
|---|---|---|
| RFA-CA-25-007-Full-Announcement.html | HTML file |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity